肾移植受者中的前列腺癌:一项全国登记研究
该研究利用瑞典肾脏登记与全国前列腺癌登记,纳入1998-2016年确诊前列腺癌的133例男性肾移植受者,比较其与一般人群及665例非移植前列腺癌对照的诊断概率与生存。结果显示移植受者诊断任何前列腺癌(OR 0.84,95%CI 0.70-0.99)或高危/转移性前列腺癌(OR 0.84,95%CI 0.62-1.13)的风险均未增加,癌症特征与特异性生存相似。
要点
- 肾移植后免疫抑制未增加前列腺癌诊断风险(OR 0.84,95%CI 0.70-0.99)。
- 高危或转移性前列腺癌风险亦未增加(OR 0.84,95%CI 0.62-1.13)。
- 移植受者与对照者的癌症特征及癌特异性生存相似。
核心结论
- 瑞典全国登记研究未提示肾移植后免疫抑制增加前列腺癌风险或恶化结局。
- 研究提示未治疗的低级别前列腺癌男性可接受肾移植。
研究设计与样本
- 基于瑞典肾脏登记与全国前列腺癌登记,纳入1998-2016年确诊前列腺癌的133例男性肾移植受者。
- 采用病例对照设计,链接PCBaSe数据库,比较移植受者与男性一般人群的诊断概率。
- 使用倾向评分匹配、Cox回归和Fisher精确检验,计算95%CI。
主要发现
- 移植受者诊断任何前列腺癌的OR为0.84(95%CI 0.70-0.99),低于年龄匹配对照。
- 高危或转移性前列腺癌的OR为0.84(95%CI 0.62-1.13)。
- 不同类别前列腺癌的OR均未随移植后时间延长而增加。
- 移植受者与665例非移植前列腺癌对照的诊断时癌症特征和癌特异性生存相似。
临床怎么用
- 肾移植候选者中未治疗的低级别前列腺癌可考虑接受移植。
- 免疫抑制不应被视为前列腺癌诊断或不良结局的危险因素。
局限性
- 登记数据未包含所有移植受者所用具体免疫抑制方案的信息。
- 近半数移植受者移植时间早于1990年代中期PSA检测普及前。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether post-transplantation immunosuppression negatively affects prostate cancer outcomes in male kidney transplant recipients. PATIENTS AND METHODS: We used the Swedish Renal Register and the National Prostate Cancer Register to identify all kidney transplantation recipients diagnosed with prostate cancer in Sweden 1998-2016. After linking these registers with Prostate Cancer Database Sweden (PCBaSe), a case-control study was designed to compare time period and risk category-specific probabilities of a prostate cancer diagnosis amongst kidney transplantation recipients versus the male general population. The registers did not include information about the specific immunosuppression agent used in all transplantation recipients. Data from PCBaSe were used to compare prostate cancer characteristics at diagnosis and survival for patients with prostate cancer with versus without a kidney transplant. Propensity score matching, Cox regression analysis and Fisher's exact test were used and 95% confidence intervals (CIs) calculated. RESULTS: Almost half of the 133 kidney transplantation recipients were transplanted before the mid-1990s, when PSA testing became common. The transplant recipients were not more likely than age-matched control men to be diagnosed with any (odds ratio [OR] 0.84, 95% CI 0.70-0.99) or high-risk or metastatic prostate cancer (OR 0.84, 95% CI 0.62-1.13). None of the ORs for the different categories of prostate cancer increased with time since transplantation. Cancer characteristics at the time of diagnosis and cancer-specific survival were similar amongst transplant recipients and the control group of 665 men diagnosed with prostate cancer without a kidney transplant. CONCLUSIONS: This Swedish nationwide, register-based study gave no indication that immunosuppression after kidney transplantation increases the risk of prostate cancer or adversely affects prostate cancer outcomes. The study suggests that men with untreated low-grade prostate cancer can be accepted for transplantation.
引用
- Bratt O, Drevin L, Prütz KG, et al. Prostate cancer in kidney transplant recipients - a nationwide register study. BJU Int. 2020. PMID: 31955497. doi:10.1111/bju.15002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。